Justia U.S. Federal Circuit Court of Appeals Opinion Summaries

Agilent Technologies, Inc. appealed two final written decisions by the Patent Trial and Appeal Board (Board) that determined all claims of U.S. Patent Nos. 10,337,001 and 10,900,034 to be unpatentable. The patents in question relate to CRISPR-Cas systems for gene editing, specifically focusing on chemically modified guide RNAs (gRNAs) used in these systems. The Board found that the claims were anticipated by prior art, specifically a reference known as Pioneer Hi-Bred, and that certain claims were also obvious in view of additional references, Threlfall and Deleavey.The Board's decisions were based on findings that Pioneer Hi-Bred disclosed the claimed gRNA functionality and that the reference was enabling. The Board also found that the additional references provided sufficient motivation and reasonable expectation of success for a person of ordinary skill in the art to combine the teachings of Pioneer Hi-Bred with those of Threlfall and Deleavey.The United States Court of Appeals for the Federal Circuit reviewed the Board's findings. The court affirmed the Board's determination that Pioneer Hi-Bred disclosed the claimed gRNA functionality, noting that substantial evidence supported the Board's findings. The court also agreed with the Board's conclusion that Pioneer Hi-Bred was an enabling reference, rejecting Agilent's arguments that undue experimentation would be required to practice the disclosed invention.Additionally, the court upheld the Board's finding that the dependent claims, which included specific chemical modifications, were obvious in view of the combined teachings of Pioneer Hi-Bred, Threlfall, and Deleavey. The court found that the Board had provided a thorough analysis and that substantial evidence supported the Board's conclusion that a person of ordinary skill in the art would have had a reasonable expectation of success in making the claimed modifications.In conclusion, the Federal Circuit affirmed the Board's decisions, holding that all claims of the '001 and '034 patents were unpatentable. View "AGILENT TECHNOLOGIES, INC. v. SYNTHEGO CORP. " on Justia Law

Albert Lobo, a Deputy Sheriff in San Bernardino County, California, contracted pneumonia in early 2010, which progressed to sepsis and resulted in multiple amputations, leaving him permanently and totally disabled. He received disability retirement and workers' compensation benefits at the county and state levels between 2012 and 2014. In March 2015, Lobo filed a claim for disability-based benefits under the Public Safety Officers’ Benefits Act of 1976 (PSOB Act) with the Public Safety Officers’ Benefits Office (PSOB Office) of the Bureau of Justice Assistance (Bureau) of the U.S. Department of Justice.The PSOB Office denied Lobo's claim in May 2016, a decision upheld by a hearing officer in October 2017 and the Bureau’s Director in August 2023. The denials were based on the finding that Lobo had not proven he contracted pneumonia in the line of duty. The Bureau's Director emphasized the lack of evidence showing that Lobo caught pneumonia at the jails where he worked, despite acknowledging that Lobo was permanently and totally disabled due to pneumonia.The United States Court of Appeals for the Federal Circuit reviewed the case. The court found that the Bureau had not made sufficient efforts to obtain potentially crucial information about whether there were pneumonia-infected individuals at the jails where Lobo worked. The court noted that such information could be highly material to determining the origin of Lobo's pneumonia. Consequently, the court vacated the Director’s decision and remanded the case for further proceedings, instructing the Bureau to make reasonable efforts to obtain the necessary information from the jails and to reassess the claim in light of any new evidence obtained. View "Lobo v. Department of Justice" on Justia Law

Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (Fraunhofer) is a non-profit research organization that developed and patented multicarrier modulation (MCM) technology used in satellite radio. In 1998, Fraunhofer granted WorldSpace International Network, Inc. (WorldSpace) an exclusive license to its MCM technology patents. Fraunhofer also collaborated with XM Satellite Radio (XM) to develop a satellite radio system, requiring XM to obtain a sublicense from WorldSpace. XM later merged with Sirius Satellite Radio to form Sirius XM Radio Inc. (SXM), which continued using the XM system. In 2010, WorldSpace filed for bankruptcy, and Fraunhofer claimed the Master Agreement was terminated, reverting patent rights to Fraunhofer. In 2015, Fraunhofer notified SXM of alleged patent infringement and filed a lawsuit in 2017.The United States District Court for the District of Delaware initially dismissed the case, ruling SXM had a valid license. The Federal Circuit vacated this decision and remanded the case. On remand, the district court granted summary judgment for SXM, concluding Fraunhofer's claims were barred by equitable estoppel due to Fraunhofer's delay in asserting its rights and SXM's reliance on this delay to its detriment.The United States Court of Appeals for the Federal Circuit reviewed the case and reversed the district court's summary judgment. The Federal Circuit agreed that Fraunhofer's delay constituted misleading conduct but found that SXM did not indisputably rely on this conduct in deciding to migrate to the high-band system. The court noted that SXM's decision was based on business pragmatics rather than reliance on Fraunhofer's silence. The case was remanded for further proceedings to determine if SXM relied on Fraunhofer's conduct and if it was prejudiced by this reliance. View "Fraunhofer-Gesellschaft v. Sirius XM Radio Inc." on Justia Law

Abigail Stratton filed a petition with the Office of Special Masters under the National Childhood Vaccine Injury Act, alleging that the Gardasil® vaccine caused her to develop postural orthostatic tachycardia syndrome (POTS) and autonomic dysfunction. These conditions are not listed in the Vaccine Injury Table, requiring her to prove actual causation by a preponderance of the evidence. After filing a Notice of Intent to Withdraw to pursue her claim in federal district court, the Chief Special Master concluded the proceedings on the merits and later awarded her partial attorneys’ fees and costs.The Secretary of Health and Human Services opposed the fee application, arguing that Stratton did not file her petition with the good faith intent of litigating the claim and that there was no reasonable basis for her claim. The Chief Special Master found that Stratton had satisfied both the good faith and reasonable basis requirements and awarded partial fees. The Court of Federal Claims affirmed the Chief Special Master’s decision, concluding that the finding of a reasonable basis was not arbitrary and capricious, and awarded $8,876.86 for attorneys’ fees and costs. The Secretary appealed this decision.The United States Court of Appeals for the Federal Circuit reviewed the case and found that the Chief Special Master failed to adequately explain the determination that Stratton’s petition had a reasonable basis. The court noted that the Chief Special Master acknowledged the Secretary’s concerns about the sufficiency of the medical records but dismissed them without sufficient explanation. The Federal Circuit vacated the decision and remanded the case for further proceedings consistent with its opinion, requiring a more detailed explanation of why the evidence provided a reasonable basis for Stratton’s claim. View "Stratton v. Health and Human Services" on Justia Law

Dolby Laboratories Licensing Corporation (Dolby) owns U.S. Patent No. 10,237,577, which is directed to a prediction method using an in-loop filter. Unified Patents, LLC (Unified) filed a petition for inter partes review (IPR) challenging claims 1, 7, and 8 of the patent as anticipated and obvious. Unified certified it was the sole real party in interest (RPI). Dolby identified nine other entities it believed should also have been named as RPIs. The Patent Trial and Appeal Board (Board) declined to adjudicate whether these entities were RPIs and instituted the review with Unified as the sole RPI. The Board ultimately held that Unified failed to show any of the challenged claims were unpatentable.The Board's final written decision did not address the RPI dispute, explaining that there was no evidence any of the alleged RPIs were time-barred or estopped from bringing the IPR, or that Unified purposefully omitted any RPIs to gain an advantage. Dolby appealed the Board's decision, arguing that the Board's refusal to adjudicate the RPI dispute caused various harms, including potential breaches of license agreements, conflicts of interest, improper estoppel in future proceedings, and disincentivizing Unified from filing IPRs.The United States Court of Appeals for the Federal Circuit reviewed the case. The court held that Dolby failed to establish an injury in fact sufficient to confer standing to appeal. The court found Dolby's claims of harm to be too speculative, noting that Dolby did not provide evidence of any actual or imminent injury. The court dismissed the appeal for lack of standing and did not reach the merits of Dolby's substantive challenges. View "Dolby Laboratories Licensing Corporation v. Unified Patents, LLC" on Justia Law

The Department of Veterans Affairs (VA) issued a request for quotes for leasing a cranial surgical navigation system. Beacon Point Associates LLC submitted a quote, which included a payment schedule and terms stating the government must exercise all renewal options if it obtained sufficient funds. The VA awarded the contract to Beacon Point, which included the same payment schedule but did not explicitly incorporate the terms of Beacon Point’s quote.The Civilian Board of Contract Appeals dismissed Beacon Point’s appeal for failure to state a claim, determining that the contract did not incorporate the terms of Beacon Point’s quote. Beacon Point then appealed to the United States Court of Appeals for the Federal Circuit.The United States Court of Appeals for the Federal Circuit reviewed the case and affirmed the Board’s decision. The court held that the contract did not incorporate Beacon Point’s quote by reference. The court noted that the contract’s reference to the quote in block 29 did not clearly communicate an intent to incorporate the quote’s terms into the contract. The court emphasized that incorporation by reference requires clear and express language, which was absent in this case. Consequently, the VA retained complete discretion to exercise the option years as per the incorporated Federal Acquisition Regulation (FAR) clauses, and Beacon Point could not rely on the terms of its quote as binding obligations on the VA. The court affirmed the Board’s dismissal of Beacon Point’s appeal. View "Beacon Point Associates LLC v. Department of Veterans Affairs" on Justia Law

Two Italian pasta manufacturers, La Molisana S.p.A. and Valdigrano Di Flavio Pagani S.r.L., challenged the United States Department of Commerce's final results from the twenty-third administrative review of an antidumping order on certain pasta from Italy. The dispute centered on Commerce's methodology for determining the protein content of pasta, which affects the classification of pasta as either standard or premium quality. Commerce used the protein content listed on product labels, which is subject to U.S. FDA rounding rules and different nitrogen-to-protein conversion factors in the U.S. and Italy. La Molisana argued that this methodology caused inaccuracies in comparing pasta products.The United States Court of International Trade sustained Commerce's final results, concluding that La Molisana had not demonstrated that the alleged flaws in Commerce's methodology were commercially significant. The court found that Commerce's reliance on packaging labels for protein content fostered transparency and consistency, and that La Molisana's evidence, including a market report and a new definition from the Bologna Grain Exchange, was insufficient to compel a change in the protein breakpoint from 12.5% to 13.5%.The United States Court of Appeals for the Federal Circuit reviewed the case and found that Commerce's methodology failed to compare products based on identical physical characteristics, as required by statute. The court held that the FDA rounding rules and different nitrogen conversion factors introduced inaccuracies that Commerce could not dismiss as commercially insignificant. However, the court agreed with Commerce and the Trade Court that La Molisana's evidence did not provide a compelling reason to change the protein breakpoint. The Federal Circuit vacated the Trade Court's judgment regarding the rounding rules and nitrogen conversion factors, affirmed the judgment on the protein breakpoint, and remanded for further proceedings. View "La Molisana S.p.A. v. United States" on Justia Law

Alnylam Pharmaceuticals, Inc. filed two lawsuits against Moderna, Inc., ModernaTX, Inc., and Moderna US, Inc. (collectively Moderna) in the District Court for the District of Delaware. Alnylam alleged that Moderna’s mRNA-based COVID-19 vaccine SPIKEVAX® infringed U.S. Patent Nos. 11,246,933 and 11,382,979, which cover cationic lipids used for delivering nucleic acids. The dispute centered on the interpretation of the term “branched alkyl” in the patent claims, specifically whether it required a carbon atom bound to at least three other carbon atoms.The District Court for the District of Delaware concluded that Alnylam had acted as a lexicographer in defining “branched alkyl” in the patent specification. The court adopted Moderna’s proposed construction, which required that a “branched alkyl” must have a carbon atom bound to at least three other carbon atoms. Based on this construction, the parties stipulated that Moderna did not infringe the asserted patent claims, as Moderna’s product did not meet this requirement. The district court entered final judgment of noninfringement accordingly.The United States Court of Appeals for the Federal Circuit reviewed the case and affirmed the district court’s decision. The Federal Circuit agreed that the specification’s definition of “branched alkyl” was clear and unequivocal, requiring a carbon atom bound to at least three other carbon atoms. The court found no evidence in the claims, specification, or prosecution history that specified otherwise for the asserted claims. Consequently, the Federal Circuit upheld the district court’s claim construction and the resulting judgment of noninfringement. View "ALNYLAM PHARMACEUTICALS, INC. v. MODERNA, INC. " on Justia Law

General Jeffrey Bannister enlisted in the Army in 1979 and was married to Patricia Erickson from 1980 to 1996. As part of their divorce proceedings, General Bannister agreed to elect Ms. Erickson as his Survivor Benefit Plan (SBP) annuity beneficiary. In 1998, General Bannister married Trese Bannister. In 2017, he requested voluntary retirement, effective May 31, 2018, and elected Mrs. Bannister as his SBP annuity beneficiary. However, General Bannister died on May 27, 2018, before his retirement. Both Ms. Erickson and Mrs. Bannister submitted claims for the SBP annuity, and the Defense Finance and Accounting Service (DFAS) awarded it to Ms. Erickson based on the 1996 separation agreement.Mrs. Bannister appealed to the Defense Office of Hearings and Appeals (DOHA) and the Army Board for Correction of Military Records (ABCMR), both of which upheld the decision to award the annuity to Ms. Erickson. Mrs. Bannister then appealed to the United States Court of Federal Claims, which denied her motion and granted the government's motion, concluding that 10 U.S.C. § 1448(d)(3) precluded Mrs. Bannister from receiving the annuity.The United States Court of Appeals for the Federal Circuit reviewed the case. The court held that 10 U.S.C. § 1448(d) governs the entitlement to General Bannister’s SBP annuity because he died on active duty before retirement. The court determined that Mrs. Bannister is the correct beneficiary under § 1448(d)(1), which defaults to the surviving spouse. The court found that the exception under § 1448(d)(3) for a former spouse did not apply because Ms. Erickson failed to submit a timely written request for a deemed election as required by § 1450(f)(3). Consequently, the court reversed the decision of the Court of Federal Claims and remanded for a determination of the annuity benefits due to Mrs. Bannister. View "BANNISTER v. US " on Justia Law

Larry B. Herrington, a veteran who served in the U.S. Air Force, filed a claim in September 2009 for service connection for several gastrointestinal conditions, including Barrett’s disease, chronic gastritis, reflux disease, and hiatal hernia. The Department of Veterans Affairs (VA) regional office awarded service connection for gastroesophageal reflux disease (GERD) with a non-compensable evaluation. The Board of Veterans’ Appeals (Board) later awarded a 30% evaluation for GERD by analogy to the diagnostic code for hiatal hernia, Diagnostic Code (DC) 7346, but denied an evaluation in excess of 30%.The United States Court of Appeals for Veterans Claims (Veterans Court) affirmed the Board’s decision, concluding that the Board’s selection of DC 7346 was not arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law. Mr. Herrington appealed this decision, arguing that the Veterans Court should have applied a de novo standard of review rather than the deferential standard set forth in 38 U.S.C. § 7261(a)(3)(A).The United States Court of Appeals for the Federal Circuit reviewed the case and determined that the selection of an analogous diagnostic code for rating unlisted conditions involves questions of fact or the application of law to facts, which requires a deferential standard of review. The court concluded that the Veterans Court applied the correct standard of review and affirmed the decision of the Veterans Court. The Federal Circuit held that the Board’s selection of DC 7346 for rating Mr. Herrington’s GERD was appropriate and supported by the evidence. View "HERRINGTON v. COLLINS " on Justia Law